Author

Silvio Danese 1

1 Vita-Salute San Raffaele Uni

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, Rachel Duan, Kristina Kligys, Marla C. Dubinsky

A CASE OF POST-GASTRECTOMY ANASTOMOTIC LEAKAGE REFRACTORY TO ENDOSCOPIC VACUUM THERAPY, SAVED BY COVERED ESOPHAGEAL STENTING

Alberto Barchi, Francesco Vito Mandarino, Lorella Fanti, Edi Viale, Paolo Biamonte, Riccardo Rosati, Silvio Danese

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Laurent Peyrin-Biroulet, Alessandro Armuzzi, Raja Atreya, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charlie Lees, Edouard Louis, Milan Lukas, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

AN ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT HISTOLOGICAL REMISSION AND PREDICT CLINICAL OUTCOMES IN ULCERATIVE COLITIS PATIENTS

Marietta Iacucci, Tommaso Lorenzo Parigi, Rocio del Amor, Pablo Meseguer, Giulio Mandelli, Anna Bozzola, Alina Bazarova, Pradeep Bhandari, Raf Bisschops, Silvio Danese, Gert De Hertogh, Jose Ferraz, Martin Götz, Enrico Grisan, Xianyong Gui, Bu Hayee, Ralf Kiesslich, Mark Lazarev, Remo Panaccione, Adolfo Parra-Blanco , L

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

William Sandborn, Bal R. Bhandari, Charles Randall, Ziad Younes, Tomasz Romańczyk, Hao Chai, Matthew McKevitt, Sally Zhao, Bittoo Kanwar, John Sundy, Satish Keshav, Silvio Danese

Anti-adhesion therapies

Silvio Danese

Assessment of Budesonide MMX® effectiveness for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the prospective multi-center observational study CORE Practice

Grażyna Rydzewska, Kristine Paridaens, Silvio Danese, Maciej Jesionowski

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Silvio Danese

Item 1 - 10 / 179
1
2 3 4 5 6 7
...
17 18